Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration.
Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.
HEMATOPOIETIC STEM CELLS
STEM CELL TRANSPLANTATION
GRAFT VERSUS HOST DISEASE
Interested in our innovative technology?
Cellect Biotechnology Ltd. to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016
Kfar Saba, Israel – August 25, 2016 – Cellect Biotechnology Ltd. (Nasdaq: “APOP”, TASE: “APOP”), a developer of innovative technology which enables the functional selection of stem cells, today announced that Dr. Shai Yarkoni, Chief Executive Officer, will present a corporate overview at the 18th Annual Rodman & Renshaw Global Investment Conference, which is being […]
Kfar Saba, Israel, July 29, 2016 – Cellect Biotechnology Ltd. (NASDAQ: APOP, APOPW; TASE: CLBD), a developer of innovative technology which enables the functional selection of stem cells, today announced the pricing of its initial public offering in the United States of 1,292,308 American Depository Shares (“ADSs”) and warrants to purchase up to 969,231 ADSs. […]